Cytokine Expression in Multiple Myeloma and Monoclonal Gammopathy: Analysis by Reverse Transcription/Polymerase Chain Reaction and Quantitative PCR

References

• Bataille R., Chappard I D., Marcelli C., Dessauw P., Baldet P., Sany J., Alexandre C. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. Journal of Clinical Investigation 1991; 88: 62–66
   PubMed Web of Science ®Google Scholar
• Klein B., Bataille R. Cytokine network in human multiple myeloma. Multiple Myeloma. Hematology/Oncologv Clinics of North America, 6. WB Saunders, Philadelphia 1992; 273–284
   Google Scholar
• Hirano T., Taga T., Nakano K., Yasukawa K., Kashiwamura S., Shimizu K., Nakajima K., Pyun K. H., Kishimoto T. Purification to homogeneity and characterisation of human B-cell differentiation factor (BCDF or BSFp-2). Proceedings of the National Academy of Science of the USA 1985; 82: 5490–5494
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X-G., Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reelection of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation 1989; 84: 2008–2011
   PubMed Web of Science ®Google Scholar
• Nachbaur D. M., Herold M., Maneschg A., Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: corrrelation with disease activity and other prognostic parameters. Annals of Hematology 1991; 62: 54–58
   PubMed Web of Science ®Google Scholar
• Teppo A.-M., Metsarinne K., Fyhrquist F. Radio-immunoassay of interleukin-6 in plasma. Clinical Chemistry 1991; 37: 1691–1695
   PubMed Web of Science ®Google Scholar
• Solary E., Guiget M., Zeller V., Casasnovas R.-O., Caillot D., Chavanet P., Guy H., Mack G. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. American Journal of Hematology 1992; 39: 163–171
   PubMed Web of Science ®Google Scholar
• Ludwig H., Nachbaur D. M., Fritz E., Krainer M., Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991; 77: 2794–2795
   PubMed Web of Science ®Google Scholar
• Thaler J., Fechner F., Herold M., Huber H. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index. Leukemia and Lymphoma 1994; 12: 265–271
   PubMed Web of Science ®Google Scholar
• Reibnegger G., Krainer M., Herold M., Ludwig H., Wachter H., Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Research 1991; 51: 6250–6253
   PubMed Web of Science ®Google Scholar
• Pelliniemi T.-T., Iriala K., Mattila K., Pulkki K., Rajamaki A., Tienhaara A., Laakso M., Lahtinen R. Serum immunoreactive interleukin-6 (IL-6) and acute phase proteins as prognostic factors in multiple myeloma. Blood 1993; 82: 262a, suppl 1)
   PubMed Web of Science ®Google Scholar
• Kyle R. A. Why better prognostic features for multiple myeloma are needed. Blood 1994; 83: 1713–1716
   PubMed Web of Science ®Google Scholar
• Brown R., Joshua I D., Uhr E., Snowdon L., Gibson J. The use of a commercially available immunoassay to determine the level of interleukin-6 in the serum of patients with myeloma. Leukemia and Lymphoma 1991; 5: 151–155
   PubMed Web of Science ®Google Scholar
• Merico F., Bergui L., Gregoretti M. G., Ghia P., Aimo G., Lindley I. J. D., Caligaris-Cappio F. Cytokines involved in the progression of multiple myeloma. Clinical and Experimental Immunology 1993; 92: 27–31
   PubMed Web of Science ®Google Scholar
• Ballester O. F., Moscinski L. C., Lyman G. H., Chaney J. V., Saha H. I., Spiers A. S. D., Klein C. High levels of Interleukin-6 are associated with low tumour burden and low growth fraction in multiple myeloma. Blood 1994; 83: 1903–1908
   PubMed Web of Science ®Google Scholar
• Ishimi Y., Miyaura C., Jin C. H., Akatsu T., Abe E., Nakamura Y., Yamaguchi A., Yoshiki S., Matsuda T., Hirano T., Kishimoto T., Suda T. IL-6 is produced by osteoblasts and induces hone resorption. Journal of Immunology 1990; 145: 3297–3303
   PubMed Web of Science ®Google Scholar
• Garrett I. R., Durie B. G. M., Nedwin G. E., Gillespie A., Bringman T., Sabatini M., Bertoloini D. R., Mundy G. R. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. New England Journal of Medicine 1987; 317: 526–532
   PubMed Web of Science ®Google Scholar
• Kawano M., Yamamoto I., Iwato K., Tanaka H., Asaoku H., Tanabe O., Ishikawa H., Nobuyoshi M., Ohmoto Y., Hirai Y., Kuramoto A. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989; 73: 1646–1649
   PubMed Web of Science ®Google Scholar
• Cozzolino F., Torcia M., Aldinucci D., Rubartelli A., Miliani A., Shaw A., Lansdorp P., Di Guglielmo R. Production of Interleukin-1 by bone marrow myeloma cells. Blood 1989; 74: 380–387
   PubMed Web of Science ®Google Scholar
• Portier M., Zhang X-G., Ursule E., Lees D., Jourdan M., Bataille R., Klein B. Cytokine expression in human multiple myeloma. British Journal of Haematology 1993; 85: 514–520
   PubMed Web of Science ®Google Scholar
• Medical research council's working party on leukaemia in adults. Prognostic features in the third MRC myelomatosis trial. British Journal of Cancer 1980; 42: 831–840
   PubMed Web of Science ®Google Scholar
• Chomczynski P., Sacchi N. Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Annals of Biochemistry 1987; 162: 156–159
   Web of Science ®Google Scholar
• Kwok S., Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237–238
   PubMed Web of Science ®Google Scholar
• Deveraux J., Haeberli P., Smithies O. A comprehensive set of sequence analysis for the VAX. Nucleic Acids Research 1984; 12: 387–395
   PubMed Web of Science ®Google Scholar
• Ralston S. H. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. Journal of Bone and Mineral Research 1994; 9: 883–890
   PubMed Web of Science ®Google Scholar
• Wang A. M., Doyle M. V., Mark D. F. Quantitation of mRNA by the polymerase chain reaction. Proceedings of The National Academy of Science of the United Sates of America 1989; 86: 9717–9721
   PubMed Web of Science ®Google Scholar
• Horton R. M., Hunt H. D., Ho S. N., Pullen J. K., Pease L. R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap etension. Gene 1989; 77: 61–668
   PubMed Web of Science ®Google Scholar
• Piatak M., Luk K.-C., Williams B., Lifson J. D. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. BioTechniques 1993; 14: 70–79
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.-G., Lu Z.-Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863–872
   PubMed Web of Science ®Google Scholar
• Al-Humidan A., Ralston S. H., Hughes D. E., Chapman K., Aarden L., Russell R. G. G., Gowen M. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. Journal of Bone and Mineral Research 1991; 6: 3–7
   PubMed Web of Science ®Google Scholar
• Kyle R. A. Multiple myeloma. Review of 869 cases. Mayo Clinic Proceedings 1975; 50: 29–40
   PubMed Web of Science ®Google Scholar
• Soutar R. L., Wilson B., Dawson A. A. Myeloma in North East Scotland revisited. British Journal of Haematology 1993; 84: 45., suppl 1
   Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-21IL-6 for human multiple myelomas. Nature 1988; 332: 83–84
   PubMed Web of Science ®Google Scholar
• Zhang X.-G., Klein B., Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11–13
   PubMed Web of Science ®Google Scholar
• Suematsu S., Matsuda T., Aozasa K., Akira S., Nakano N., Ohno S., Miyazaki J., Yamamura K., Hirano T., Kishimoto T. IgGI plasmacytosis in interleukin 6 transgenic mice. Proceedings of The National Academy of Science of the United States of America 1989; 86: 7547–7551
   PubMed Web of Science ®Google Scholar
• Klein B., Wijdenes J., Zhang X.-G., Jourdan M., Boiron J.-M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B., Lu Z.-Y., Mannoni P., Sany J., Bataille R. Murine anti-interleukin—6 monoclonal antibody therapy for a patient with plasma cell leukaemia. Blood 1991; 75: 1198–1204
   Google Scholar
• Janowska-Wieczorek A., Belch A. R., Jacobs A., Bowen D., Padua R.-A., Paietta E., Stanley E. R. Increased circulating colony-stimulating factor-1 in patients with preleukaemia, leukaemia, and lymphoid malignancies. Blood 1991; 77: 1796–1803
   PubMed Web of Science ®Google Scholar
• Freeman G. J., Freedman A. S., Rabinowe S. N., Segil J. M., Horowitz J., Rosen K., Whitman J. F., Nadler L. M. Interleukin 6 gene expression in normal and neoplastic B cells. Journal of Clinical Investigation 1989; 83: 1512–1518
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.-G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by Interleukin-6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Suzuki A., Takahashi T., Okuno Y., Fukumoto M., Fukui H., Koishihara Y., Ohsugi Y., Ohno Y., Imura H. Estimation of Interleukin 6 production by reverse transcriptionpolymerase chain reaction in four human myeloma cell lines. Leukaemia Research 1991; 15: 1043–1050
   PubMed Web of Science ®Google Scholar